Anemia and Other Blood Disorder Drugs Market Report 2026

The anemia and other blood disorder drugs market size has grown strongly in recent years. It will grow from $12.46 billion in 2025 to $13.14 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high incidence of iron deficiency anemia, prevalence of chronic kidney disease, reliance on blood transfusions, long-standing use of esAs, established hematology treatment protocols.

The anemia and other blood disorder drugs market size is expected to see strong growth in the next few years. It will grow to $16.88 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to growth in gene therapy adoption, increasing aging population, rising awareness of blood disorders, expansion of specialty hematology clinics, improved diagnostic rates. Major trends in the forecast period include rising prevalence of chronic blood disorders, increasing use of injectable therapies, expansion of gene therapy for rare anemias, growing focus on personalized hematology treatments, improved access to essential blood disorder drugs.

The increasing demand for personalized medicine is anticipated to drive the growth of the anemia and other blood disorder drugs market in the coming years. Personalized medicine is a medical approach that utilizes an individual’s genetic profile to guide prevention, diagnosis, and treatment decisions. The demand for personalized medicine is growing due to its capacity to provide more effective, targeted therapies that enhance patient outcomes and long-term health. The anemia and other blood disorder drugs market facilitates personalized care by enabling tailored treatment plans that address specific genetic or molecular characteristics of blood disorders. For example, in May 2024, according to the American Psychiatric Association, a US-based non-profit organization, 43% of adults reported feeling more anxious than the previous year, up from 37% in 2023 and 32% in 2022. As a result, the rising demand for personalized medicine is fueling the growth of the anemia and other blood disorder drugs market.

Major companies operating in the anemia and other blood disorder drugs market are concentrating on launching innovative medications to enhance therapeutic outcomes, broaden treatment options, and reinforce their competitive standing. Innovative medications are pharmaceutical therapies that provide new mechanisms of action, greater efficacy, or improved safety profiles compared to existing treatments, addressing unmet needs in conditions such as anemia and myelodysplastic syndromes. For example, in August 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, obtained FDA approval for Reblozyl as the first-line treatment of anemia in adults with lower-risk myelodysplastic syndromes, representing the first therapy to demonstrate superiority over an erythropoiesis-stimulating agent in this context. This approval was supported by Phase 3 COMMANDS trial data showing that nearly twice as many Reblozyl-treated patients achieved at least 12 weeks of transfusion independence with concurrent hemoglobin improvement compared to those receiving Epoetin alfa.

In April 2023, Vertex Pharmaceuticals Inc., a US-based biotechnology company, extended its long-standing collaboration with CRISPR Therapeutics to advance exagamglogene autotemcel (exa-cel), a CRISPR/Cas9 gene-editing therapy for sickle cell disease and transfusion-dependent β-thalassemia. The partnership reinforces Vertex’s position in the anemia and blood-disorder therapeutics market by accelerating regulatory progress and supporting the late-stage development of a potential one-time curative treatment, while boosting CRISPR Therapeutics’ clinical and commercial impact by combining its gene-editing platform with Vertex’s development, regulatory, and commercialization expertise. CRISPR Therapeutics is a Switzerland- and US-based biotechnology company focused on CRISPR-based gene-editing therapies.

Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.

North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anemia and other blood disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of imported biologics, excipients, and injectable drug components used in anemia treatment manufacturing. These impacts are most pronounced in developing regions that rely heavily on imported therapeutic inputs. Rising tariff related expenses have placed pressure on production costs and public healthcare procurement budgets. This has influenced pricing negotiations and availability of injectable anemia therapies. However, tariffs are also supporting domestic drug manufacturing, local formulation capabilities, and improved supply security over the long term.

The anemia and other blood disorder drugs market research report is one of a series of new reports that provides anemia and other blood disorder drugs market statistics, including anemia and other blood disorder drugs industry global market size, regional shares, competitors with a anemia and other blood disorder drugs market share, detailed anemia and other blood disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anemia and other blood disorder drugs industry. This anemia and other blood disorder drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anemia and other blood disorder drugs are medications used to treat anemia and various blood disorder conditions. This refers to a blood condition that occurs when a medication triggers the body's immune system to attack its own red blood cells. Hemolysis, a process that leads to the premature breakdown of red blood cells, is caused by this.

The main categories of drugs for anemia and other blood disorders include iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia, and aplastic anemia. Iron deficiency anemia is a prevalent form of anemia in which the blood lacks a sufficient number of healthy red blood cells. These oxygen-carrying red blood cells are responsible for transporting oxygen to the body’s tissues. The various types of anemia include microcytic (low MCV), normocytic (normal MCV), and macrocytic (high MCV), and they are available in different forms of administration such as oral and injectable. These drugs are distributed through hospitals, pharmacies, online pharmacies, and retail pharmacies.

The anemia and other blood disorder drugs market consists of sales of folate analogues, multivitamin and mineral supplements, iron supplements, and erythropoiesis-stimulating agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.